



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-------------------------------|-------------|----------------------|---------------------|------------------|
| 09/779,334 | 02/08/2001 | Carsten Sjoeholm | 6092.200-US | 9041 |
| 25908 | 7590 | 08/19/2005 | EXAMINER | |
| NOVOZYMES NORTH AMERICA, INC. | | | HARLE, JENNIFER I | |
| 500 FIFTH AVENUE | | | ART UNIT | |
| SUITE 1600 | | | PAPER NUMBER | |
| NEW YORK, NY 10110 | | | 1654 | |

DATE MAILED: 08/19/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | | |
|---|------------------------|---------------------|--|
| Response to Rule 312 Communication | Application No. | Applicant(s) | |
| | 09/779,334 | SJOEHOLM ET AL. | |
| | Examiner | Art Unit | |
| | Jennifer I. Harle | 1654 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. ☒ The amendment filed on 16 March 2005 under 37 CFR 1.312 has been considered, and has been:

a) ☐ entered.

b) ☐ entered as directed to matters of form not affecting the scope of the invention.


c) ☐ disapproved because the amendment was filed after the payment of the issue fee.

Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.

d) ☐ disapproved. See explanation below.

e) ☒ entered in part. See explanation below.

The changes to the drawings have also been entered. Please note that the new drawings are attached, as the examiner has had to amend them to conform with the drawing practice, i.e. the examiner added "REPLACEMENT DRAWING" at the top of each of FIGS. 1-6/ The changes to the Specification have been entered amended claims have not been entered because Applicants' deletion of purified in line one of claim 28 would cause line 4 of claim 28 to lack antecedent basis and moreover, the substilin has to be derived or purified or in some way obtained in order to be acid-stable.




BRUCE R. CAMPELL, PH.D
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600



REPLACEMENT DRAWING


Figure 1





REPLACEMENT DRAWING


Figure 2





REPLACEMENT DRAWING


Figure 3





REPLACEMENT DRAWING


Figure 4






REPLACEMENT DRAWING

Figure 5





REPLACEMENT DRAWING

Figure 6

